A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas
Annals of Oncology, 06/13/2012
Reyners AKL et al. – The findings suggest that celecoxib did not influence progression–free survival (PFS) and overall survival (OS), but interpretation of results is hampered by premature celecoxib discontinuation.



